Company intelligence / Profile preview

NEUVOGEN

San Diego, California, United Statesneuvogen.com ↗
Ownership
Private
Employees
~250
Development stage
Preclinical
01

Overview

NEUVOGEN has completed pre-clinical validation of its technology platform. Early data shows potential to meaningfully improve and extend the lives of patients suffering from a broad spectrum of solid tumors[2].

Therapeutic areas
Oncology
Modalities
Therapeutic whole cell cancer vaccines
Industry
Biotech
02

Drug pipeline

9 assets

NGEN-241

Preclinical

8 more assets in the full pipeline.

Beyond the preview

Go deeper on NEUVOGEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEUVOGEN.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call